What's New

Last Posted: Jul 16, 2023

• Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas
  S Reynolds, NCI Blog, July 2023
• Integrated Genomic DNA/RNA Profiling vs Fluorescence in Situ Hybridization in the Detection of MYC and BCL2 (and BCL6) Rearrangements in Large B-Cell Lymphomas: Updates Amid the New WHO Classification of Lymphoid Neoplasms.
  Luiz Paulo de Lima Guido et al. American journal of clinical pathology 2023
• Evaluation of a convolution neural network for baseline total tumor metabolic volume on [F]FDG PET in diffuse large B cell lymphoma.
  Karimdjee Mourtaza et al. European radiology 2023
• Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas.
  Landsburg Daniel J et al. Oncotarget 2022 131237-1244
• Multimodal deep learning model on interim [F]FDG PET/CT for predicting primary treatment failure in diffuse large B-cell lymphoma.
  Yuan Cheng et al. European radiology 2022
• Budget Impact Analysis of CAR T-cell Therapy for Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in Germany.
  Skalt Daniela et al. HemaSphere 2022 6(7) e736
• Cost-Effectiveness of Molecularly Guided Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) in Patients under 60.
  Regier Dean A et al. Cancers 2022 14(4)
• Optimal PET-based radiomic signature construction based on the cross-combination method for predicting the survival of patients with diffuse large B-cell lymphoma.
  Jiang Chong et al. European journal of nuclear medicine and molecular imaging 2022
• Artificial intelligence-assisted mapping of proliferation centers allows the distinction of accelerated phase from large cell transformation in chronic lymphocytic leukemia.
  El Hussein Siba et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2022
• High grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma.
  Ferrari Anna et al. Leukemia & lymphoma 2022 1-7
• B-cell lymphoma 6 expression is not associated with live birth in a normal responder in vitro fertilization population.
  Klimczak Amber M et al. Fertility and sterility 2021
• CT-based radiomics model with machine learning for predicting primary treatment failure in diffuse large B-cell Lymphoma.
  Santiago Raoul et al. Translational oncology 2021 14(10) 101188
• Primary Mediastinal B-Cell Lymphoma: A 2021 Update on Genetics, Diagnosis, and Novel Therapeutics.
  Ahmed Zahoor et al. Clinical lymphoma, myeloma & leukemia 2021
• Artificial intelligence to detect MYC translocation in slides of diffuse large B-cell lymphoma.
  Swiderska-Chadaj Zaneta et al. Virchows Archiv : an international journal of pathology 2020 Sep
• The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
  Braendstrup Peter et al. Cytotherapy 2020 22(2) 57-69
• Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
  Rosenwald Andreas et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 37(35) 3359-3368
• Clinical utility of target capture-based panel sequencing in hematological malignancies: a multicenter feasibility study.
  Yasuda Takahiko et al. Cancer science 2020 Jul
• Classifying 2-year recurrence in patients with dlbcl using clinical variables with imbalanced data and machine learning methods.
  Wang Lei et al. Computer methods and programs in biomedicine 2020 Jun 196105567
• Comprehensive Genomic Analysis of Noonan Syndrome and Acute Myeloid Leukemia in Adults: A Review and Future Directions.
  Alhumaid Muhned S et al. Acta haematologica 2020 Jun 1-11
• Deep learning shows the capability of high-level computer-aided diagnosis in malignant lymphoma.
  Miyoshi Hiroaki et al. Laboratory investigation; a journal of technical methods and pathology 2020 May
• An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy.
  Hu Jinglei et al. Journal of translational medicine 2020 Mar 18(1) 144
• The application of antigen receptor gene rearrangement of BIOMED-2 in the pathologic diagnosis of 348 cases with non-Hodgkin lymphoma in a single institution in Southwest of China.
  Liu Xueni et al. Pathology, research and practice 2019 Nov 215(11) 152615
• Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.
  Crombie Jennifer L et al. Surgical oncology clinics of North America 2020 Jan 29(1) 115-125
• Family Members at Higher Risk for Blood Cancers
  P Harrison, Medscape, September 9, 2019
• Opportunities in Cancer Research: The Immune System and Microbiome
  NCI 2021 annual plan, 2019
• FDA Approvals Provide Advances for a Range of Cancer Types
  K Honey, AACR Blogs, August 6, 2019
• The Use of Optimal Treatment for DLBCL Is Improving in All Age Groups and Is a Key Factor in Overall Survival, but Non-Clinical Factors Influence Treatment.
  Wong Doo Nicole et al. Cancers 2019 Jul 11(7)
• Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.
  Kurtz David M, et al. Cell 2019 7 0. (3) 699-713.e19
• Clinical Significance of BCL2 , C- MYC , and BCL6 Genetic Abnormalities, Epstein-Barr Virus Infection, CD5 Protein Expression, Germinal Center B Cell/Non-Germinal Center B-Cell Subtypes, Co-expression of MYC/BCL2 Proteins and Co-expression of MYC/BCL2/BCL6 Proteins in Diffuse Large B-Cell Lymphoma: A Clinical and Pathological Correlation Study of 120 Patients.
  Ting Choo-Yuen et al. International journal of medical sciences 2019 16(4) 556-566
• MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavourable prognosis.
  Vermaat Joost S et al. Haematologica 2019 May
• Automated Diagnosis of Lymphoma with Digital Pathology Images Using Deep Learning.
  Achi Hanadi El et al. Annals of clinical and laboratory science 2019 Mar 49(2) 153-160
• Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit.
  Kim Jinkyoung et al. Oncology letters 2019 Feb 17(2) 1812-1818
• Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
  Dunleavy Kieron et al. The Lancet. Haematology 2018 Dec 5(12) e609-e617
• Genomics of aggressive B-cell lymphoma.
  Rosenthal Allison et al. Hematology. American Society of Hematology. Education Program 2018 Nov 2018(1) 69-74
• Clinical Utility of In Situ Hybridization Assays in Head and Neck Neoplasms.
  Luk Peter P et al. Head and neck pathology 2018 Nov
• Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma.
  Wu Fang-Tian et al. Annals of hematology 2018 Oct
• Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study.
  Biccler Jorne L et al. JCO clinical cancer informatics 2018 21-13
• Dissecting aggressive B-cell lymphoma through genomic analysis - What is clinically relevant?
  Scott David W et al. Best practice & research. Clinical haematology 2018 Sep 31(3) 187-198
• Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphoma.
  Sun Chengtao et al. Bioscience reports 2019 39(1)
• Local Coverage Determination (LCD): Flow Cytometry (L33661)
  The U.S. Centers for Medicare & Medicaid Services
• Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
  Davies Andrew et al. Hematology. American Society of Hematology. Education Program 2017 2017(1) 284-294
• Mendelian randomization studies of cancer risk: a literature review.
  Pierce Brandon L et al. Current epidemiology reports 2018 Jun 5(2) 184-196
• Determination of CEBPA mutations by next generation sequencing in pediatric acute leukemia.
  Akin D F et al. Bratislavske lekarske listy 2018 119(6) 366-372
• Mutation screening using formalin-fixed paraffin-embedded tissues: a stratified approach according to DNA quality.
  Cucco Francesco et al. Laboratory investigation; a journal of technical methods and pathology 2018 May
• Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
  Marchesi Francesco et al. Journal of experimental & clinical cancer research : CR 2018 May 37(1) 95
• NIH study revises molecular classification for most common type of lymphoma
  NIH News, Apr 11, 2018
• Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi.
  Zaja Francesco et al. Leukemia & lymphoma 2018 Apr 1-7
• The Impact of Drug Metabolism Gene Polymorphisms on Therapeutic Response and Survival in Diffuse Large B-Cell Lymphoma Patients.
  Pál Ildikó et al. The Israel Medical Association journal : IMAJ 2018 Apr 20(4) 217-221
• Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.
  Dubois Sydney et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Jun 22(12) 2919-28
• Precision Medicine for Diffuse Large B-cell Lymphoma.
  Lim Megan S et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Jun 22(12) 2829-31

More